We are live on ! Find out more
EW icon

Edwards Lifesciences

1,338 hedge funds and large institutions have $47.1B invested in Edwards Lifesciences in 2026 Q2 according to their latest regulatory filings, with 144 funds opening new positions, 470 increasing their positions, 473 reducing their positions, and 104 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

38% more first-time investments, than exits

New positions opened: 144 | Existing positions closed: 104

16% more capital inflows, than outflows

Capital inflows: $4.87B | Capital outflows: $4.21B

3% more funds holding

Funds holding: 1,295 → 1,338 (+43)

3.09% more ownership

Funds ownership: 87.39% → 90.48% (+3.1%)

1% less repeat investments, than reductions

Existing positions increased: 470 | Existing positions reduced: 473

6% less call options, than puts

Call options by funds: $168M | Put options by funds: $180M

Holders
1,338
Holders Change
+43
Holders Change %
+3.32%
% of All Funds
15.93%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.12%
New
144
Increased
470
Reduced
473
Closed
104
Calls
$168​M
Puts
$180​M
Net Calls
-⁠$11.4​M
Net Calls Change
+$65.2​M

EW Hedge Fund Activity: Q2 2026 in Review

1,338 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2026, worth a combined $47.1B — up 17% from $40.3B a quarter earlier.

Buyers outnumbered sellers: 144 funds opened new EW positions and 104 closed out — a net gain of 40 holders — while 470 added to existing stakes and 473 trimmed.

The largest buyer was Aristotle Capital Management, opening a new position worth an estimated $726M. The largest seller was Jennison Associates, cutting an estimated $1.07B.

  • 1,338 institutional investors held Edwards Lifesciences (EW) as of Q2 2026, up from 1,295 in Q1 2026.
  • Funds reported $47.1B of Edwards Lifesciences stock for Q2 2026, up 17% quarter-over-quarter.
  • 144 funds opened new Edwards Lifesciences positions in Q2 2026 and 104 closed out, a net change of +40 holders.
  • The largest Edwards Lifesciences buyer in Q2 2026 was Aristotle Capital Management, an estimated $726M added.
  • The largest Edwards Lifesciences seller in Q2 2026 was Jennison Associates, an estimated $1.07B sold.

Based on aggregated 13F filings for Q2 2026.